Wilmington, DE, United States of America

Ruth Richmond Wexler

This inventor holds 31 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 8 EPO patents, primarily in Factor Xa Inhibitors. Top assignees: Bristol-Myers Squibb Compnay, Bristol-Myers Squibb Pharma Company, E.i. Dupont De Nemours and Company. Active years: 1986-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ruth Richmond Wexler. Retrieved from https://idiyas.com/inventor/ruth-richmond-wexler

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 31 

% Patents Active = 100.0

 

 

Average Co-Inventor Count = 3.9

ph-index = 13

Forward Citations = 443(Granted Patents)


Location History:

  • Wilmington, DE (US) (1986 - 2002)
  • Chadds Ford, DE (US) (2002)
  • Chadds Ford, PA (US) (2002 - 2005)
  • Belle Mead, NJ (US) (2006 - 2021)

Company Filing History:


Years Active: 1986-2025

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Factor Xa Inhibitors
Pyrimidinones
Macrocyclic Compounds
Serotonin Receptor Agonists
Tricyclic Gamma-Carbolines
Aryl Sulfonyls
Fused Heterocycles
Imidazoles
Metalloproteinase Inhibitors
Antihypertensive Derivatives
Atherosclerosis Treatment
CNS Disorders
31 patents (USPTO):Explore Patents

Title: Ruth Richmond Wexler: Pioneering Inventor Shaping the Future of Medical Treatments

Introduction

Ruth Richmond Wexler, a brilliant inventor based in Wilmington, DE (US), is renowned for her passion for innovation and unwavering dedication to creating groundbreaking solutions that aim to improve the world we live in. With an impressive track record of 30 patents under her name, Ruth's inventive spirit continues to inspire and influence generations of inventors worldwide.

Latest Patents

Among Ruth's notable inventions is the pioneering work titled "Pyrimidinones as factor XIA inhibitors." This invention introduces compounds of Formula (1) that act as selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. The pharmaceutical compositions derived from these compounds offer promising avenues for treating thromboembolic and inflammatory disorders, showcasing Ruth's remarkable impact on the field of medicine.

Career Highlights

Ruth Richmond Wexler's illustrious career includes significant stints at renowned pharmaceutical companies, with notable contributions made at Bristol-Myers Squibb Pharma Company and Bristol-Myers Squibb Company. Her innovative mindset and expertise have played a pivotal role in shaping the pharmaceutical landscape, setting new standards for medical advancements and patient care.

Collaborations

Throughout her career journey, Ruth has collaborated with esteemed peers such as Irina C Jacobson and Mimi Lifen Quan. This collaborative spirit and exchange of ideas have fueled the development of inventive solutions that continue to redefine industry practices and propel innovation in the field of medicine.

Conclusion

In conclusion, Ruth Richmond Wexler stands as a true trailblazer in the realm of invention, with her remarkable contributions leaving an indelible mark on the field of medical research and treatment. Her relentless pursuit of innovation and commitment to creating a better world serve as a beacon of inspiration for aspiring inventors and underscore the transformative power of inventions in shaping a brighter future for all.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…